Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.67 |
| ▸ | PPARA | Q07869 | 4/20 | 0.67 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.62 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.62 |
| ▸ | LTA4H | P09960 | 3/20 | 0.62 |
| ▸ | LAP3 | P28838 | 1/20 | 0.62 |
| ▸ | PPARD | Q03181 | 1/20 | 0.59 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.58 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1069493 | 1.00 | PPARG (0.67) | PPARGPPARAFFAR1FFAR4LTA4H | |
| SCHEMBL287969 | 1.00 | PPARG (0.67) | PPARGPPARAFFAR1FFAR4LTA4H | |
| SCHEMBL14501335 | 0.88 | MAOB (0.60) | PPARGPPARAFFAR1FFAR4LTA4H | |
| SCHEMBL27854776 | 0.88 | LTA4H (0.71) | PPARGPPARAFFAR1FFAR4LTA4H | |
| SCHEMBL4756304 | 0.87 | PPARG (0.57) | PPARGPPARAFFAR1FFAR4LTA4H | |
| SCHEMBL7801265 | 0.87 | PPARA (0.70) | PPARGPPARAFFAR1FFAR4LTA4H | |
| SCHEMBL5309375 | 0.85 | LTA4H (0.72) | PPARGPPARAFFAR1FFAR4LTA4H | |
| SCHEMBL10272384 | 0.85 | ALOX5 (0.58) | PPARGPPARAFFAR1FFAR4LTA4H | |
| SCHEMBL6732617 | 0.85 | LTA4H (0.72) | PPARGPPARAFFAR1FFAR4LTA4H | |
| SCHEMBL2164928 | 0.85 | LTA4H (0.72) | PPARGPPARAFFAR1FFAR4LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3024816-B1 | PPAR-SPARING COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | METABOLIC SOLUTIONS DEV CO LLC (US) | 2020-06-03 | — | — | EP | disclosed |
| US-9562012-B2 | PPAR-sparing compounds for the treatment of metabolic diseases | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160152570-A1 | PPAR-SPARING COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | ALZHEIMER'S DRUG DISCOVERY FOUNDATION | 2016-06-02 | — | — | US | disclosed |
| EP-3024816-A1 | PPAR-SPARING COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | Metabolic Solutions Development Company LLC (US) | 2016-06-01 | — | — | EP | disclosed |
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2016-02-25 | — | — | US | disclosed |
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2016-02-25 | — | — | US | disclosed |
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2016-02-25 | — | — | US | disclosed |
| EP-2931274-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Metabolic Solutions Development Company LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| WO-2015013187-A1 | PPAR-SPARING COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT CO., LLC (US) | 2015-01-29 | — | — | WO | disclosed |
| WO-2014093114-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY LLC (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20090176770-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-09 | — | — | US | disclosed |
| US-20090111797-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-7491717-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-17 | — | — | US | disclosed |
| US-7479488-B2 | Selected CGRP—antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-20 | — | — | US | disclosed |
| WO-2008010238-A2 | ANTIDIABETIC AZABICYCLO [3. 1. 0] HEXAN COMPOUNDS | LUPIN LIMITED (IN) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008010238-A2 | ANTIDIABETIC AZABICYCLO [3. 1. 0] HEXAN COMPOUNDS | LUPIN LIMITED (IN) | 2008-01-24 | — | — | WO | disclosed |
| CN-1976916-A | Selected CGRP-antagonists, method for the production thereof and their use as medicaments | BOEHRINGER INGELHEIM INT (DE) | 2007-06-06 | — | — | CN | disclosed |
| EP-1732917-A1 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2006-12-20 | — | — | EP | disclosed |
| US-20060252750-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | US | disclosed |
| WO-2005092880-A1 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176770-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | PPARG 2294/4885PPARA 3147/4885FFAR1 1012/4885 |
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | PPARD, PPARG, PPARA | PPARG 2/4885PPARA 3/4885FFAR1 45/4885 |
| US-20060252750-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | PPARG 2294/4885PPARA 3147/4885FFAR1 1012/4885 |
| US-20090111797-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | PPARG 2294/4885PPARA 3147/4885FFAR1 1012/4885 |
| US-20160152570-A1 | PPAR-SPARING COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885FFAR1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.